1. Reporting pharmacoeconomic evaluations

   • C. I. Carswell
   • J. A. Paladino

   Editorial 17 September 2012 Pages: 1073 - 1073

2. Economic evaluations of healthcare programmes and decision making

   • Marieke E. van Velden
   • Johan L. Severens
   • Annoesjka Novak

   Review Article 17 September 2012 Pages: 1075 - 1082

   

3. Antiviral agents for influenza

   • Larry D. Lynd
   • Ron Goeree
   • Bernie J. O’Brien

   Review Article 17 September 2012 Pages: 1083 - 1106

   

4. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US

   • Ralph P. Insinga
   • Erik J. Dasbach
   • Elamin H. Elbasha

   Review Article 17 September 2012 Pages: 1107 - 1122

   

5. Acute pyelonephritis among adults

   • Patricia Brown
   • Moran Ki
   • Betsy Foxman

   Review Article 17 September 2012 Pages: 1123 - 1142

   

6. Eliciting social preference weights for Functional Assessment of Cancer Therapy-Lung health states

   • Paul Kind
   • Susan Macran

   Original Research Article 17 September 2012 Pages: 1143 - 1153

   

7. Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer

   • Niels Neymark
   • Pilar Lianes
   • Jan P. van Meerbeeck

   Original Research Article 17 September 2012 Pages: 1155 - 1166

   

8. The importance of drug adverse effects compared with seizure control for people with epilepsy

   • Andrew Lloyd
   • Emma McIntosh
   • Martin Price

   Original Research Article 17 September 2012 Pages: 1167 - 1181